Abstract
We have recently characterized a series of 3-amino-2-phenyl-propene (APP) derivatives as reversible inhibitors for the bovine adrenal chromaffin granule vesicular monoamine transporter (VMAT) that have been previously characterized as potent irreversible dopamine-β-monooxygenase (DβM) and monoamine oxidase (MAO) inhibitors. Halogen substitution on the 4′-position of the aromatic ring gradually increases VMAT inhibition potency from 4′-F to 4′-I, parallel to the hydrophobicity of the halogen. We show that these derivatives are taken up into both neuronal and non-neuronal cells, and into resealed chromaffin granule ghosts efficiently through passive diffusion. Uptake rates increased according to the hydrophobicity of the 4′-substituent. More importantly, these derivatives are highly toxic to human neuroblastoma SH-SY5Y but not toxic to M-1, Hep G2, or human embryonic kidney 293 non-neuronal cells at similar concentrations. They drastically perturb dopamine (DA) uptake and metabolism in SH-SY5Y cells under sublethal conditions and are able to deplete both vesicular and cytosolic catecholamines in a manner similar to that of amphetamines. In addition, 4′-IAPP treatment significantly increases intracellular reactive oxygen species (ROS) and decreases glutathione (GSH) levels in SH-SY5Y cells, and cell death is significantly attenuated by the common antioxidants α-tocopherol, N-acetyl-l-cysteine and GSH, but not by the nonspecific caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone. DNA fragmentation analysis further supports that cell death is probably due to a caspase-independent ROS-mediated apoptotic pathway. Based on these and other findings, we propose that drastic perturbation of DA metabolism in SH-SY5Y cells by 4′-halo APP derivatives causes increased oxidative stress, leading to apoptotic cell death.
Footnotes
-
This work was supported by National Institutes of Health grant NS39423 and a United States Department of Education Graduate Assistance in Areas of National Need Fellowship.
-
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
-
doi:10.1124/mol.107.035873.
-
ABBREVIATIONS: DA, dopamine; NE, norepinephrine; E, epinephrine; ROS, reactive oxygen species; b561, cytochrome b561; V-H+, vesicular H+; DβM, dopamine-β-monooxygenase; VMAT, vesicular monoamine transporter; Asc, ascorbic acid; DAT, dopamine transporter; MPP+, 1-methyl-4-phenylpyridinium; APP, 3-amino-2-phenylpropene; OHAPP, hydroxy-3-amino-2-phenylpropene; MAO, monoamine oxidase; GSH, reduced glutathione; GBR 12909, vanoxerine; Z-VAD-FMK, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone; FBS, fetal bovine serum; HPLC, high-performance liquid chromatography; HPLC-EC, HPLC with electrochemical detection; HPLC-UV, HPLC with UV detection; DMEM, Dulbecco's modified Eagle's medium; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NAC, N-acetyl-cysteine; KRB, Krebs-Ringer buffer; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; DCF-DA, 2′,7′-dichlorofluorescein diacetate; DCF, 2′,7′-dichlorofluorescein; MCB, monochlorobimane.
- Received March 7, 2007.
- Accepted June 14, 2007.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|